Weight Loss
Buy weight loss and fat loss research compounds in Canada! Semaglutide, Tirzepatide, Cardarine (GW501516), T3 (Liothyronine), Clenbuterol, AOD-9604, DNP and more, shipped domestically from within Canada. Every compound is third party tested with a certificate of analysis on file. The most complete weight loss research catalogue available from a domestic Canadian supplier.
Canada's most trusted domestic source for weight loss and metabolic research compounds. GLP-1 receptor agonists, thyroid hormones, beta-2 agonists, PPARδ agonists, and peptide based fat loss compounds. All sourced, tested, and dispatched same day from within Canada with no customs and no cross border delays.
![Topiramate Topamax 25mg - 100 Tablets [weight loss ]](https://www.canadasteroiddepot.is/wp-content/uploads/2026/04/TOPIRAMATE-25-300x300.png "Topiramate Topamax 25mg - 100 Tablets [weight loss ] 22")
Weight Loss Compounds in Canada | GLP-1 Agonists, Thyroid Hormones & Metabolic Research
Canada Steroid Depot's weight loss category covers the most extensively researched compound classes for fat loss, metabolic rate enhancement, and body composition optimization. From GLP-1 receptor agonists that have revolutionized obesity pharmacology research, to thyroid hormone analogues that directly increase basal metabolic rate, to beta-2 agonists that enhance lipolysis and thermogenesis, to peptide based fat loss compounds that target specific metabolic pathways. Each compound class operates through distinct mechanisms, and many are researched in combination protocols for synergistic fat loss effects.
GLP-1 receptor agonists | Semaglutide and Tirzepatide
GLP-1 receptor agonists represent the most significant pharmacological advancement in obesity research in decades. Semaglutide: the active compound in Ozempic and Wegovy is a GLP-1 receptor agonist that reduces appetite through central hypothalamic mechanisms, slows gastric emptying, improves insulin sensitivity, and produces profound sustained weight reduction in clinical research with Phase III trials demonstrating 15–17% body weight reduction over 68 weeks at therapeutic doses. Tirzepatide is a dual GIP and GLP-1 receptor agonist that demonstrated superior weight reduction outcomes compared to Semaglutide in head to head trials with Phase III data showing up to 22.5% body weight reduction. CSD stocks both compounds in lyophilized vial and pre-filled pen formats for research applications.
Thyroid hormones | T3 and T4
Thyroid hormones are the primary regulators of basal metabolic rate with T3 (Liothyronine) being the metabolically active form that directly increases cellular oxygen consumption and thermogenesis by upregulating mitochondrial activity. In research contexts, exogenous T3 is studied for its ability to elevate metabolic rate above baseline, enhancing fat oxidation and accelerating weight loss particularly in combination with other fat loss compounds. T4 (Levothyroxine) is the prohormone converted to T3 in peripheral tissues. In anabolic research, T3 is commonly researched alongside thermogenic compounds and caloric restriction protocols. Exogenous thyroid hormone use suppresses endogenous TSH and thyroid hormone production requiring a gradual taper on discontinuation to restore normal thyroid axis function.
Beta-2 agonists | Clenbuterol and Albuterol
Beta-2 adrenergic agonists produce fat loss through direct stimulation of beta-2 receptors on adipocytes; activating hormone sensitive lipase and increasing lipolysis, while simultaneously increasing metabolic rate through thermogenic effects on brown adipose tissue. Clenbuterol is the most extensively researched beta-2 agonist for fat loss, producing significant increases in core body temperature, metabolic rate, and lipolytic activity. It also demonstrates anti catabolic properties through beta-2 receptor activation in muscle tissue. Making it particularly relevant in cutting research protocols where lean mass preservation alongside fat loss is the objective. Albuterol (Salbutamol) is a shorter-acting beta-2 agonist with a more favourable cardiac side effect profile compared to Clenbuterol, increasingly researched as an alternative.
Peptide fat loss compounds | AOD-9604 and CJC-1295
AOD-9604 is a synthetic analogue of the C-terminal fragment of human growth hormone (hGH176-191) studied specifically for its fat reducing properties without the growth promoting, insulin desensitizing, or IGF-1-elevating effects of full length HGH. It stimulates lipolysis and inhibits lipogenesis through a mechanism independent of the GH receptor, making it one of the most targeted peptide fat loss compounds available. CJC-1295 and Ipamorelin. Growth hormone secretagogues are also researched for their fat loss applications through the GH-mediated lipolytic effects of the GH pulse they stimulate, alongside their body composition and recovery benefits. CSD stocks all three compounds in lyophilized vial format.
Frequently asked questions
CSD stocks Semaglutide, Tirzepatide, T3 (Liothyronine), T4 (Levothyroxine), Clenbuterol, Albuterol, AOD-9604, Cardarine (GW501516), CJC-1295, Ipamorelin, and more. Check the category page for current availability, dosing configurations, and stock status.
Semaglutide is a GLP-1 receptor agonist that produces appetite suppression and metabolic improvements through GLP-1 pathway activation. Demonstrating 15–17% body weight reduction in Phase III trials. Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously, producing superior weight reduction outcomes up to 22.5% body weight reduction in Phase III trials. Tirzepatide also demonstrates greater improvements in insulin sensitivity and metabolic markers compared to Semaglutide in head to head research.
T3 (Liothyronine) directly increases cellular metabolic rate by upregulating mitochondrial oxidative phosphorylation. Increasing basal metabolic rate, oxygen consumption, and thermogenesis. In research fat loss protocols, exogenous T3 elevates metabolic rate above baseline, increasing the caloric deficit achievable at a given food intake level. T3 is non selective in its catabolic effects; it accelerates both fat and muscle catabolism, making adequate protein intake and concurrent anabolic compound use important considerations in T3-inclusive fat loss research protocols.
Clenbuterol produces measurable fat loss through beta-2 receptor mediated lipolysis and thermogenesis. Research demonstrates significant increases in core temperature, metabolic rate, and fat oxidation. Its additional anti catabolic properties through muscle beta-2 receptor activation make it particularly researched for cutting protocols where lean mass preservation is a concurrent objective. Beta-2 receptor downregulation occurs with continuous use. Research protocols typically incorporate 2 weeks on, 2 weeks off cycling to maintain receptor sensitivity.
AOD-9604 is a synthetic analogue of the C-terminal fragment of HGH (amino acids 176–191) that stimulates lipolysis and inhibits lipogenesis through a mechanism independent of the insulin-like growth factor pathway. Unlike full HGH, AOD-9604 does not raise IGF-1, does not promote hyperglycaemia, and does not produce growth effects making it a highly targeted fat loss peptide without the metabolic complications associated with full length HGH administration at supraphysiological doses.
All orders ship from within Canada via tracked Canada Post or courier. Peptide and temperature sensitive compounds are shipped in insulated packaging. Packages are plain and discreet with no identifying product information on the exterior. Most orders arrive within 2–5 business days depending on your province. Express shipping is available at checkout. Orders over $250 qualify for free shipping Canada wide.